Bar Harbor Wealth Management’s Quest Diagnostics DGX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$3.94M Buy
18,585
+127
+0.7% +$24.9K 0.21% 95
2026
Q1
$3.62M Buy
18,458
+950
+5% +$185K 0.21% 100
2025
Q4
$3.04M Buy
17,508
+926
+6% +$169K 0.18% 109
2025
Q3
$3.16M Buy
16,582
+1,403
+9% +$249K 0.19% 104
2025
Q2
$2.73M Buy
+15,179
New +$2.64M 0.17% 110
2019
Q4
Sell
-4,416
Closed -$473K 292
2019
Q3
$473K Sell
4,416
-1,770
-29% -$182K 0.05% 204
2019
Q2
$630K Sell
6,186
-12
-0.2% -$1.15K 0.07% 184
2019
Q1
$557K Buy
6,198
+791
+15% +$68.5K 0.07% 183
2018
Q4
$450K Sell
5,407
-1,064
-16% -$99.8K 0.06% 195
2018
Q3
$698K Buy
6,471
+237
+4% +$26K 0.08% 183
2018
Q2
$686K Buy
6,234
+1,398
+29% +$146K 0.08% 172
2018
Q1
$485K Buy
+4,836
New +$495K 0.06% 202

Other funds holding DGX

Bar Harbor Wealth Management's DGX Position: Q2 2026 in Review

Bar Harbor Wealth Management increased its Quest Diagnostics (DGX) stake by 0.69% in Q2 2026, buying an estimated $24.9K and bringing the position to 18,585 shares worth $3.94M. The position accounts for 0.21% of the portfolio, ranked #95.

Bar Harbor Wealth Management first reported a position in DGX in Q1 2018 and has held it in 12 quarters since. 152 funds tracked by Wall St. Rank hold DGX as of Q2 2026.

  • Bar Harbor Wealth Management held 18,585 shares of Quest Diagnostics worth $3.94M as of Q2 2026.
  • Bar Harbor Wealth Management bought 127 Quest Diagnostics shares in Q2 2026, an estimated $24.9K.
  • Quest Diagnostics made up 0.21% of Bar Harbor Wealth Management's portfolio in Q2 2026, its #95 holding.
  • Bar Harbor Wealth Management first reported a position in Quest Diagnostics in Q1 2018 and has held it in 12 quarters since.
  • 152 funds tracked by Wall St. Rank held Quest Diagnostics as of Q2 2026.

Based on Bar Harbor Wealth Management's 13F filing for Q2 2026, filed 15 Jul 2026.